Status | Study |
Not yet recruiting |
Study Name: Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea Condition: Essential Thrombocythemia Date: 2017-04-17 Interventions: Drug: Ruxolitinib Ruxolitinib |
Not yet recruiting |
Study Name: 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia Condition: Essential Thrombocythemia Primary Myelofibrosis, Fibrotic Stage Date: 2017-04-04 Interventions: Device: Diagnostic (18F-FLT PET/CT) The tracer compound [F-18] FLT will be injected into the patient's v |
Recruiting |
Study Name: Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) Condition: Myelofibrosis Essential Thrombocythemia Date: 2016-11-01 |
Recruiting |
Study Name: The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Condition: Essential Thrombocythemia Date: 2016-10-05 Interventions: Drug: Anagrelide Anagrelide in |
Not yet recruiting |
Study Name: Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia Condition: MPN Essential Thrombocythemia Date: 2015-10-13 Interventions: Other: Aspirin therapy interruption |
Recruiting |
Study Name: The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Condition: Polycythemia Vera (PV) Essential Thrombocythemia (ET) Date: 2015-10-01 Interventions: Drug: Ruxolitinib Ruxolitinib |
Recruiting |
Study Name: Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia Condition: Polycythemia Vera Essential Thrombocythemia Date: 2015-03-24 Interventions: Drug: RG7388 RG7388 is supplie |
Completed |
Study Name: Anagrelide Retard in Essential Thrombocythemia Condition: Essential Thrombocythemia Date: 2014-02-13 Interventions: Drug: Anagrelide retard Overen |
Terminated |
Study Name: Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia Condition: Polycythemia Vera Essential Thrombocythemia Date: 2013-11-25 Interventions: Drug: Momelotinib Momelotinib tablet administered orally once daily |
Completed |
Study Name: Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Condition: Essential Thrombocythemia (ET) Date: 2011-10-31 Interventions: Drug: SPD422 (anagrelide hydrochloride) Subjects will be continued on the dose of anagrelide that contro |